Study of Zanzalintinib in People with Moderate Liver Problems
Treatments studied
Part of Digestive system clinical trials.
This trial looks at how a drug called Zanzalintinib acts in people with moderate liver impairment compared to healthy volunteers. It aims to ensure the drug is safe and at the right dose for people with liver issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have moderate liver impairment (Child-Pugh Class B, score 7-9) or be a healthy volunteer.
- You must be a non-smoker or light smoker (≤10 cigarettes/day) and willing to stay at the clinic.
- You must have stable liver disease (no major changes in the last 2 months) if you have liver impairment.
- You must not have donated blood in the past 30 days.
- You must not have a history of liver transplant or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This study tests a combination of three drugs (zanzalintinib, durvalumab, and tremelimumab) for people with liver cancer that cannot be removed by surgery and who have not received prior systemic treatment. The goal is to see if this combination can shrink or slow the growth of the cancer.
This study tests an oral drug called zanzalintinib in children and teens with certain solid tumors that have come back or not responded to treatment. The goal is to see if the drug is safe and works against the cancer.
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
This trial tests a combination of two drugs, zanzalintinib and durvalumab, as a maintenance treatment for people with advanced liver cancer (hepatocellular cancer) that has not gotten worse after initial treatment with tremelimumab and durvalumab. The goal is to see if this combination can help keep the cancer from growing.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.